Malignant Glioma of Brain Clinical Trial
Official title:
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
Fluorescence-guided resection using 5-ALA induced tumor fluorescence of malignant gliomas allows for better identification of tumor tissue and more radical resection in select patients and improvements in progression-free and overall survival. With new developments in surgical microscopy, the development of digital exoscopes have provided advanced visualization as well as improvements in ergonomics and accessibility of the surgical field. The use of the exoscope in 5-ALA fluorescence-guided tumor surgery has the potential to enhance the ability of the surgeon to remove brain tumors with high efficacy. While algorithms for use of 5-ALA fluorescence have been optimized for use with traditional microscopes, the use of fluorescence techniques in newer digital exoscopes have not been developed. The primary outcome of the study is to obtain parameters to optimize visualization of fluorescence intensity and perform optimization based on the intensities achieved. The operating ORBEYE exoscope will be fitted with a blue light filter. All experiments will be performed in darkened operating rooms. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. Patients (experimental group) will receive 5ALA treatment before operation, blue light filter imagining will take place after tacking up dura and prior to direct resection. The expected outcomes of image analysis will be to have a set of exoscope parameters optimized for visualization of 5ALA tissue in different tumor types. This 5ALA characterization of visualization parameters has never been completed on an exoscope. Optimizing ORBEYE exoscope parameters will define a standard in glioma resection using 5ALA under a novel exoscopic filter as well as contribute insight into the use of the fluorescent filter for additional tumor types.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03011671 -
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
|
Phase 1 | |
| Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
| Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
| Completed |
NCT03355794 -
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
|
Phase 1 | |
| Recruiting |
NCT03423992 -
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
|
Phase 1 | |
| Not yet recruiting |
NCT04482933 -
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT06417281 -
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）
|
Phase 3 | |
| Withdrawn |
NCT03176160 -
LITT Palliative Treatment for Patients With Malignant Gliomas
|
||
| Recruiting |
NCT02839954 -
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03152318 -
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
|
Phase 1 | |
| Completed |
NCT00870181 -
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
|
Phase 2 | |
| Completed |
NCT01550523 -
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
|
Phase 1 | |
| Terminated |
NCT01017653 -
Panitumumab and Irinotecan for Malignant Gliomas
|
Phase 2 |